Ian Ingram is the Deputy Managing Editor for MedPage Today, a leading source of medical news and information for healthcare professionals. With a focus on medical research and advancements, Ian covers a wide range of topics including oncology, hematology, and drug approvals.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Ian Ingram's coverage is primarily focused on healthcare and pharmaceuticals, with a particular emphasis on clinical trial results, FDA approvals, and drug treatments for cancer and leukemia. He frequently cites data in his articles, indicating an interest in evidence-based reporting.
Pitching to Ian should involve providing access to newly released or exclusive clinical trial data, insights from key opinion leaders in the field of oncology or pharmaceuticals regarding recent developments in cancer treatment or FDA approval processes.
It's important to note that Ian does not have a specific geographic focus but covers international healthcare and pharmaceutical topics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
— Benralizumab wins approval for eosinophilic granulomatosis with polyangiitis
Drugmaker none-too-pleased with agency's request for additional studies
— Phase III trial program showed 30% to 34% reduction in moderate or severe exacerbations
Dupilumab lands expanded indication for upper airway disease
— In confirmatory trial, antibody-drug conjugate failed to improve OS versus chemotherapy
— SGLT1/SGLT2 inhibitor has another shot in T1D, but now in more narrow patient population
— Antibiotic Emrosi topped doxycycline, placebo in phase III trials
— Obecabtagene autoleucel has no requirement for a REMS program The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating
— Agency's decision on obeticholic acid in PBC follows negative advisory committee meeting
Targeted preventive strategies needed, especially for younger women, researchers say
(833) 317-6278 
